GlassScriptPhysician profile
Kristopher Joel Wise
NPI 1679230148
$390.60
in general payments reported to CMS, 2019-2025
13 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $71.46 · 2024: $165 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $390.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.98 | 2023-2025 | Xifaxan |
| Organon LLC | $61.97 | 2024-2025 | Nexplanon, Nuvaring |
| Janssen Pharmaceuticals, INC | $41.34 | 2024 | Spravato |
| Dexcom, INC. | $39.43 | 2023-2024 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $32.31 | 2025 | Farxiga, Airsupra |
| Exact Sciences Corporation | $26.40 | 2024 | Cologuard Collection Kit |
| Cipher Pharmaceuticals US LLC | $20.55 | 2025 | Natroba, Spinosad |
| Takeda Pharmaceuticals U.S.A., INC. | $19.64 | 2025 | Eohilia |
| Vanda Pharmaceuticals INC. | $18.65 | 2025 | Fanapt |
| Lilly USA, LLC | $18.56 | 2024 | Mounjaro |
| Halozyme INC | $18.49 | 2023 | |
| Novo Nordisk INC | $17.80 | 2025 | Rybelsus, Ozempic |
| Neurocrine Biosciences, INC. | $13.48 | 2024 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristopher Wise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.